A Phase 1 Open-Label, Multicenter, Single and Multiple Ascending Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Lurasidone in Subjects 6 to 17 Years Old With Schizophrenia Spectrum, Bipolar Spectrum, Autistic Spectrum Disorder, or Other Psychiatric Disorders
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2015
At a glance
- Drugs Lurasidone (Primary)
- Indications Autistic disorder; Bipolar disorders; Psychotic disorders
- Focus Pharmacokinetics
- Sponsors Sunovion Pharmaceuticals
- 26 Nov 2015 Results published in the Clinical Therapeutics
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Dec 2012 Planned number of patients changed from 60 to 100 as reported by ClinicalTrials.gov.